The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
VAD‐based regimens as primary treatment for multiple myeloma
Abstract
An alternating VCAD‐VAD regimen, combining vincristine‐doxorubicin by continuous infusion with cyclophosphamide and pulse dexamethasone, or VAD alone, was given to 175 previously untreated patients with multiple myeloma. The response rate with primary VAD‐based regimens of 55% was virtually identical to the 54% in comparable patients treated previously with similar programs by using bolus vincristine‐doxorubicin. Despite responses to VAD that were more rapid in onset than any previous treatment, remission and survival times were similar. This may be due to major differences in drug sensitivity between progenitor and differentiated plasma cells. A VAD‐based regimen seems better for newly diagnosed patients when rapid control of multiple myeloma is necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents
Barlogie, B., Smith, L., & Alexanian, R. (1984) · New England Journal of Medicine · doi:10.1056/nejm198405243102104 · Cited by 641
Self-citationHigh-dose melphalan with autologous bone marrow transplantation for multiple myeloma
Barlogie, B., Hall, R., Zander, A., Dicke, K., & Alexanian, R. (1986) · Blood · doi:10.1182/blood.v67.5.1298.1298 · Cited by 340
Self-citationHigh-Dose Glucocorticoid Treatment of Resistant Myeloma
ALEXANIAN, R., BARLOGIE, B., & DIXON, D. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-8 · Cited by 248
Self-citationPrognostic factors in multiple myeloma
Alexanian, R., Balcerzak, S., Bonnet, J. D., Gehan, E. A., Haut, A., Hewlett, J. S., & Monto, R. W. (1975) · Cancer · doi:10.1002/1097-0142(197510)36:4<1192::aid-cncr2820360403>3.0.co;2-i · Cited by 229
Self-citationProliferation-dependent cytotoxicity of anticancer agents: a review.
Valeriote, F. A., & van Putten, L. (1975) · PubMed · Cited by 214
Belch, A. R., Shelley, W. E., Bergsagel, D. E., Wilson, K. S., Klimo, P., White, D., & Willan, A. R. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.17 · Cited by 155
Salmon, S. E., Haut, A., Bonnet, J. D., Amare, M., Weick, J. K., Durie, B. G. M., & Dixon, D. O. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.8.453 · Cited by 154
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
Caligaris‐Cappio, F., Bergui, L., Tesio, L., Pizzolo, G., Malavasi, F., Chilosi, M., Campana, D., Camp, B. V., & Janossy, G. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112080 · Cited by 146
High Serum Levels of Lactic Dehydrogenase Identify a High-Grade Lymphoma-like Myeloma
Barlogie, B., Smallwood, L., Smith, T., & Alexanian, R. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-7-521 · Cited by 142
Self-citationMarrow cytometry and prognosis in myeloma.
Barlogie, B., Alexanian, R., Gehan, E. A., Smallwood, L., Smith, T., & Drewinko, B. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111056 · Cited by 48
Self-citation
Cited by
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Kyle, R. A., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2007-10-078022 · Cited by 855
Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Metadata
- Authors
- Alexanian, R., Barlogie, B., & Tucker, S.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 1990-02
- Volume
- 33
- Issue
- 2
- Pages
- 86-89
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W1992935261
- Cited by
- 307
- References
- 12
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: VAD‐based regimens as primary treatment for multiple myeloma. https://app.cochat.ai/papers/10.1002/ajh.2830330203
- The paper
- Alexanian, R., Barlogie, B., & Tucker, S. (1990). VAD‐based regimens as primary treatment for multiple myeloma. American Journal of Hematology. https://doi.org/10.1002/ajh.2830330203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.